Lycia Therapeutics, Inc. (NASDAQ:LYCA – Get Free Report) was the target of a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 304,185 shares. Approximately 0.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 400,880 shares, the days-to-cover ratio is currently 0.8 days.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on LYCA shares. Wall Street Zen raised Lycia Therapeutics to a “hold” rating in a report on Saturday, October 31st. Jefferies Financial Group initiated coverage on shares of Lycia Therapeutics in a report on Tuesday. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a Buy rating. Based on data from MarketBeat.com, the stock has an average rating of “Buy”.
Read Our Latest Stock Analysis on LYCA
Insider Activity at Lycia Therapeutics
In related news, major shareholder Venrock Healthcare Capital Par purchased 1,952,705 shares of the firm’s stock in a transaction that occurred on Monday, October 26th. The shares were acquired at an average price of $18.04 per share, with a total value of $35,226,798.20. Following the purchase, the insider directly owned 6,785,437 shares in the company, valued at $122,409,283.48. This represents a 40.41% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last ninety days, insiders purchased 2,078,749 shares of company stock worth $38,526,342.
Lycia Therapeutics Trading Down 8.3%
NASDAQ LYCA opened at $28.61 on Tuesday. Lycia Therapeutics has a 1-year low of $22.19 and a 1-year high of $36.49.
Lycia Therapeutics Company Profile
Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.
See Also
- Five stocks we like better than Lycia Therapeutics
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
